Maravai LifeSciences (MRVI)
(Delayed Data from NSDQ)
$2.04 USD
-0.31 (-13.03%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $2.04 +0.01 (0.25%) 5:44 PM ET
3-Hold of 5 3
D Value F Growth C Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MRVI 2.04 -0.31(-13.03%)
Will MRVI be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MRVI based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MRVI
Maravai LifeSciences Holdings, Inc. (MRVI) Reports Q1 Loss, Tops Revenue Estimates
Jushi Holdings Inc. (JUSHF) Reports Q1 Loss, Lags Revenue Estimates
MRVI: What are Zacks experts saying now?
Zacks Private Portfolio Services
MariMed Inc. (MRMD) Reports Q1 Loss, Lags Revenue Estimates
Stryker (SYK) Surpasses Q1 Earnings and Revenue Estimates
QuidelOrtho (QDEL) Surges 10.1%: Is This an Indication of Further Gains?
Other News for MRVI
Maravai LifeSciences To Host Earnings Conference Call on Monday, August 11, 2025 | MRVI Stock News
Maravai Lifesciences Holdings (MRVI) Receives a Buy from Craig-Hallum
Strategic Leadership Changes and Financial Discipline Drive Buy Rating for Maravai Lifesciences Holdings
William Blair Sticks to Its Hold Rating for Maravai Lifesciences Holdings (MRVI)
Maravai Lifesciences Appoints New CFO Rajesh Asarpota